ASX-listed Creso Pharma has signed a non-binding letter of intent with CERES Natural Remedies to distribute and sell its anibidiol range of CBD and hemp animal health products in the US with a revenue target of US$5m over two years.
CERES is a leading provider of plant-based remedies and CBD products and a subsidiary of High Fidelity, Vermont’s largest independent cannabis company which has generated more than US$35m in revenue since 2013.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.